Wednesday - September 9, 2026
Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months
August 31, 2026
NEW YORK, Aug. 31 [Category: BizHospital] -- Mount Sinai Health System posted the following news release:

* * *

Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months

*

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products